Moderna, Inc. Shareholder Class Action Update
In recent developments, investors of Moderna, Inc. (NASDAQ: MRNA) are reminded about a crucial deadline regarding a securities class action lawsuit. Bernstein Liebhard LLP is actively reaching out to shareholders to ensure they are informed of their rights and options.
Understanding the Class Action Lawsuit
The class action lawsuit concerns those who purchased Moderna securities within a specific window. If you acquired shares between January 18, 2023, and June 25, 2024, you may be eligible to be part of this class.
Key Dates to Consider
The deadline to file a lead plaintiff motion is approaching rapidly. Interested shareholders need to submit their filings no later than October 8, 2024. This motion is crucial for any investor wanting to represent their fellow class members in this litigation.
Why This Lawsuit Matters
This lawsuit emerges from allegations that Moderna misrepresented the potential of its mRNA-1345 vaccine, designed to combat respiratory syncytial virus (RSV) in older adults. Such claims underscore the importance of transparency within the pharmaceutical sector, particularly in how companies communicate about clinical trials and product viability.
Your Rights as a Shareholder
If you feel you have lost money through your investments in Moderna, now is the time to evaluate your rights closely. Investors are encouraged to engage with legal counsel or contact Bernstein Liebhard LLP to discuss their situation.
No Fees Until Recovery
One appealing aspect of this class action is that representation is offered on a contingency basis. This means shareholders won’t incur any fees or expenses unless there’s a successful recovery for the class.
Bernstein Liebhard LLP’s Track Record
Bernstein Liebhard LLP has a strong history of fighting for investor rights. Since 1993, the firm has successfully recovered over $3.5 billion for its clients, indicating a rich legacy of effective advocacy in securities law.
Connecting with Investor Relations
For those looking to participate or gather further information, you can reach out to the investor relations manager, Peter Allocco, at (212) 951-2030. He is available to assist shareholders with any inquiries about the class action or their potential involvement.
Frequently Asked Questions
1. What is a class action lawsuit?
A class action lawsuit allows a group of people with similar claims to come together to sue a defendant, in this case, Moderna, for alleged wrongdoing.
2. How do I know if I'm eligible?
If you purchased shares of Moderna, Inc. during the specified class period (January 18, 2023 to June 25, 2024), you may be eligible to participate in the class action.
3. What should I do if I want to join the lawsuit?
To join the class action, you must file a lead plaintiff motion before the deadline of October 8, 2024. It is advised to seek legal guidance.
4. Are there any costs involved?
No, there are no fees unless a recovery is achieved for the class. Bernstein Liebhard LLP operates on a contingency fee basis.
5. Who can I contact for more information?
For more details, contact Peter Allocco at Bernstein Liebhard LLP at (212) 951-2030 or reach out via email for inquiries or engagement with the lawsuit.
